Page 220 - Genentech News Today

BioNTech aims to develop the first mRNA-based vaccine for Malaria prevention based on a novel multi-antigen vaccine approachFirst evaluated candidate...

BioNTech aims to develop the first mRNA-based vaccine for Malaria prevention based on a novel multi-antigen vaccine approachFirst evaluated candidate BNT165b1 expresses certain parts of the circumsporozoite

With Lunsumio, people with heavily pre-treated follicular lymphoma may experience remission with a chemotherapy-free, fixed-duration treatment that can be accessed in an outpatient settingResults from

The first-in-class bispecific antibody mosunetuzumab-axgb (Lunsumio) has been granted an accelerated approval for use in relapsed or refractory follicular lymphoma.

Investegate announcements from F. Hoffmann-La Roche Ltd, FDA approves Roche’s Lunsumio, a first-in-class bispecific antibody, to treat people with relapsed or refractory follicular lymphoma

21.12.2022 - Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved Actemra (tocilizumab) intravenous (IV) for the treatment of COVID-19 in hospitalized adult patients ... Seite 1

These wide-moat healthcare stocks are trading below our analysts’ fair value estimates.

KRAKOW, Poland, Dec. 22, 2022 (GLOBE NEWSWIRE) -- Ryvu Therapeutics [WSE:RVU], a clinical-stage drug discovery and development company focusing on novel...

Investegate announcements from BioNTech SE, BioNTech and Fosun Pharma Provide COVID-19 Vaccine Doses For Vaccination of German Expatriates in China

Approximately 11,500 of the companies' mRNA-based COVID-19 vaccine doses arrived on the Chinese Mainland to enable vaccination campaign for German expatriatesVaccines expected to be available in Beijing